• IHC results (immunohistochemistries to detect relative protein abundance, markers for certain cancers and personalized therapies).
• FISH results (fluorescent in situ hybridization identifying gene copy number differences and chromosomal rearrangements in the tumor).
• DNA sequencing results, microarray, and PCR (monitoring changes that have occurred at the DNA and RNA levels in tumors, indicative of mutations within specific signaling pathways- important for evaluating targeted drug therapies).
• Proteomics (changes in protein expression and/or modification within biosamples).
• Circulating tumor cells (an emerging technology, still in development).

Additional services to be offered by the Mimi Martin Molecular Profiling Program at ICAN:

• Review and analysis of the patient's pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history, diet, lifestyle and risk factors, current condition as well as any co-morbid conditions; and complete review of symptoms prior to presentation.
• Referrals, at the patient's request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, anesthesiologists, pathologists and additional specialists relevant to the patient's ongoing care, who are all adept in the field of molecular oncology and who have the skill sets to position a patient's treatment plan with molecular profiling in mind.
• Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
• Referrals to cancer-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
• Review of the nature/amelioration of specific side effects from chemotherapy (such as nausea and neuropathy) as well as from other treatment modalities.
• Discussion of the interaction of diet and cancer chemotherapy drugs based on recent studies.
• Delineation of the symptoms about which the patient should alert his/her oncologist.
• Discussion of relevant imaging technology.
• Explanation of the recommendations given or not given by the patient's physicians; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
• Review of the relevant radiotherapy/interventional radiology options which the patient contact, in turn, may discuss with his/her medical team.
• Discussion of the relevance of the patient's specific immunohistochemistry and cytogenetic results to available clinical trials so that the patient may explore all options with his/her medical team.
• Analysis of relevant clinical trials options as well as the nature and purpose of clinical trials based on molecular profiling.
• Review of relevant cancer-specific drugs in the anticancer pipeline.
• Review of all relevant and complementary and alternative medicine ("CAM") avenues.
• Review of the merits of filing a "Single Patient IND for Compassionate or Emergency Use" for a specific experimental cancer drug, if relevant to the patient's situation, based on molecular profiling.
• Analysis of relevant cancer clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.